Welcome to our dedicated page for Innovate SEC filings (Ticker: VATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
INNOVATE Corp.'s SEC filings document a diversified holding company with Infrastructure, Life Sciences and Spectrum portfolio interests. Form 8-K reports furnish earnings releases, investor presentations, subsidiary dividend announcements, and portfolio-company events involving DBM Global and MediBeacon, including regulatory updates for the MediBeacon TGFR System.
The filings also identify VATE common stock listed on the New York Stock Exchange and preferred stock purchase rights. Proxy materials cover governance matters, executive compensation, equity awards, and pay-versus-performance disclosures, while event reports and exhibits provide formal records of operating results, Regulation FD presentations, and other public-company disclosures.
INNOVATE Corp. reported that MediBeacon, in which it holds a 44.7% equity interest, had a peer-reviewed article on its transdermal GFR (tGFR) measurement recognized as one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology.
The featured work describes MediBeacon’s TGFR System, which uses the Lumitrace (relmapirazin) fluorescent tracer and a wearable sensor to measure kidney function through the skin at the point of care. The article was featured on the journal’s August 2025 cover.
The TGFR System is approved for human use, and commercialization through centers of excellence in select academic medical centers began in January 2026, initially focusing on heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE Corp. filed a current report to note that one of its portfolio companies, referred to as Global, plans to pay a cash dividend. The company disclosed this by issuing a press release titled “INNOVATE’s Portfolio Company Global to Pay Cash Dividend,” which is included as an exhibit.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings. The report also includes the cover page interactive data file as Exhibit 104.
INNOVATE Corp. reported that on December 16, 2025 it issued a press release titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval,” announcing that this MediBeacon system has received FDA approval. This highlights a notable regulatory milestone for that product.
The company is sharing the news with investors through the press release, which is attached as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into Securities Act filings. INNOVATE’s common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the symbol VATE.
Whitefort Capital Management, with David Salanic and Joseph Kaplan, filed Amendment No. 1 to Schedule 13G reporting 7.8% beneficial ownership of INNOVATE Corp. (VATE), totaling 1,059,897 shares as of September 30, 2025.
The position comprises 743,000 shares plus $13,409,255 principal amount of the issuer’s 9.5% convertible senior notes due 2027, currently convertible into 316,897 shares. The percentage is based on 13,336,149 shares outstanding as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the reported shares and certify the securities were not acquired to change or influence control.
INNOVATE Corp. (VATE) filed its Q3 2025 10‑Q, reporting stronger topline but continued losses and a going concern warning. Revenue rose to $347.1 million from $242.2 million a year ago, led by Infrastructure ($338.4 million). Gross profit was $49.7 million.
Net loss attributable to common and participating preferred was $9.4 million (loss per share $0.71) versus $15.3 million (loss per share $1.18) last year. Year‑to‑date operating cash flow improved to $45.5 million from $(32.3) million.
The company disclosed substantial doubt about its ability to continue as a going concern, citing upcoming maturities of Corporate, Spectrum, and R2 Technologies debt and cross‑default provisions under its 10.50% 2027 Senior Secured Notes. Current portion of debt was $571.8 million at September 30, 2025. Remaining performance obligations at DBM Global totaled $1.54 billion ($1.13 billion within one year). As of November 7, 2025, shares outstanding were 13,655,062.
INNOVATE Corp. (VATE) furnished its Q3 2025 results update. The company announced results for the three and nine months ended September 30, 2025 via a press release and investor presentation, furnished under Items 2.02 and 7.01.
Exhibits include the Earnings Release (99.1) and Third Quarter 2025 Conference Call Investor Presentation (99.2). A conference call and simultaneous webcast are scheduled for November 12, 2025 at 4:30 p.m. ET on the Investor Relations section of the company’s website.
INNOVATE Corp. filed an 8-K announcing a press release titled “MediBeacon receives regulatory approval to sell the Transdermal GFR System in China.” The company states the press release is attached as Exhibit 99.1.
Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into Securities Act filings unless specifically referenced.
INNOVATE Corp. filed an 8-K announcing that its portfolio company, DBM Global, plans to pay a cash dividend. The company issued a press release titled “INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend” on October 16, 2025, which is attached as Exhibit 99.1.
The press release is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced in a future filing. INNOVATE’s common stock trades on the NYSE under the symbol VATE.
INNOVATE Corp. (VATE) Form 4/A shows amended insider reporting by Avram A. Glazer, related trust and affiliates reflecting conversions of company convertible notes. The amendment adds Lancer Capital LLC as an additional reporting owner and clarifies indirect ownership through the Avram Glazer Irrevocable Exempt Trust and familial relationships.
The filing shows convertible instruments with a $42.3143 conversion price. For the 9.5% Convertible Senior Notes due 2027, the filing reports beneficial ownership of 2,195,000 common shares following the reported transaction, held indirectly through Lancer Capital. Signatures are dated 09/18/2025.
INNOVATE Corp. (VATE) Form 4/A shows amended insider reporting by Avram A. Glazer, related trust and affiliates reflecting conversions of company convertible notes. The amendment adds Lancer Capital LLC as an additional reporting owner and clarifies indirect ownership through the Avram Glazer Irrevocable Exempt Trust and familial relationships.
The filing shows convertible instruments with a $42.3143 conversion price. For the 9.5% Convertible Senior Notes due 2027, the filing reports beneficial ownership of 2,195,000 common shares following the reported transaction, held indirectly through Lancer Capital. Signatures are dated 09/18/2025.
Paul Voigt, Interim CEO of INNOVATE Corp. (VATE), reported the grant of three stock option awards on 09/15/2025. Each award covers 100,000 underlying shares of common stock for a total of 300,000 optioned shares, and each is reported as direct ownership. Exercise prices shown are $5.67, $4.22 and $25.00. The $5.67 exercise price was set at 110% of the 10-day VWAP on the grant date, per the filing. Listed exercisability and expiration dates include ranges through 09/15/2035 for one award and earlier expirations for others. The form is signed by Mr. Voigt and filed on 09/17/2025.
Paul Voigt, Interim CEO of INNOVATE Corp. (VATE), reported the grant of three stock option awards on 09/15/2025. Each award covers 100,000 underlying shares of common stock for a total of 300,000 optioned shares, and each is reported as direct ownership. Exercise prices shown are $5.67, $4.22 and $25.00. The $5.67 exercise price was set at 110% of the 10-day VWAP on the grant date, per the filing. Listed exercisability and expiration dates include ranges through 09/15/2035 for one award and earlier expirations for others. The form is signed by Mr. Voigt and filed on 09/17/2025.